motilal oswal
Financial Services

8 November 2025
2QFY26 Results Update | Sector: Healthcare

Torrent Pharma

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	TRP IN
Equity Shares (m)	338
M.Cap.(INRb)/(USDb)	1211.6 / 13.7
52-Week Range (INR)	3790 / 2886
1, 6, 12 Rel. Per (%)	0/4/8
12M Avg Val (INR M)	1203

Financials & Valuations (INRb)

Y/E March	FY26E	FY27E	FY28E
Sales	130.3	143.4	166.4
EBITDA	42.6	49.2	58.1
Adjusted PAT	23.7	28.6	35.3
EBIT Margin (%)	26.3	28.0	29.3
Cons. Adj EPS (INR)	70.0	84.6	104.2
EPS Gr. (%)	21.2	20.8	23.1
BV/Sh. (INR)	538.1	646.2	779.2
Ratios			
Net D-E	0.3	0.2	0.1
RoE (%)	28.4	28.6	29.2
RoCE (%)	22.7	24.5	26.6
Payout (%)	36.4	36.1	36.1
Valuation			
P/E (x)	51.1	42.3	34.4
EV/EBITDA (x)	28.6	24.3	20.2
Div. Yield (%)	0.6	0.7	0.9
FCF Yield (%)	2.3	2.8	3.3
EV/Sales (x)	9.4	8.3	7.0

Shareholding Pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	68.3	68.3	71.3
DII	9.3	8.7	7.1
FII	15.9	16.1	14.5
Others	6.5	6.9	7.2

FII includes depository receipts

CMP: INR3,580 TP: INR3,770 (+5%) Neutral

Execution gains in DF/LATAM/US

Softness in EU persists in 2Q; valuation limits upside

- Torrent Pharma (TRP) delivered in-line financial performance for the quarter. YoY growth improved in the US generics and LATAM markets, led by new product launches and steady market share gains in the base portfolio.
- After a slowdown in the LATAM business in FY25, TRP has revived growth in this segment, outperforming the market over the past two quarters. Product approvals and enhanced marketing efforts have driven higher YoY growth. The company has already submitted the application for Semaglutide and is well-positioned to benefit from this opportunity, given its strong brand franchise in this market.
- In the Domestic Formulation (DF) segment, TRP faced minimal impact from the GST transition and outperformed the industry. Notably, it recorded a higher YoY volume growth of 3.7% vs the industry (0.5%) in 2QFY26.
- Following the receipt of a voluntary action indicated (VAI) at its US site in Aug'24, the business has recorded healthy growth over the past two quarters, driven largely by new product launches.
- We largely maintain our estimates for FY26/FY27/FY28. We value TRP at 40x 12M forward earnings to arrive at a TP of INR3,770. TRP remains well-positioned to deliver industry-leading growth in DF/LATAM. While current product launches have enabled a pick-up in the US growth, the pace of filings is expected to accelerate from FY27 onwards. Temporary disruptions continue to impact the EU business in the near term. Considering all these factors, we expect a 13%/16%/23% revenue/EBITDA/PAT CAGR over FY25-28. Integration and synergy benefits from the JB acquisition are expected to materialize following the completion of the acquisition process. Considering the limited upside from current levels, we reiterate Neutral on the stock.

Sales/EBITDA rise 14%/15% YoY; PAT grows at a high rate of 33% due to lower tax rate

- Sales grew 14.3% YoY to INR33b.
- DF revenue grew 11.5% YoY to INR18.2b (55% of sales). US generics grew 25.7% YoY to INR3.4b (10% of sales). LATAM business grew 21% YoY to INR3.2b (10% of sales). ROW+CDMO sales grew 19.6% YoY at INR5.2b (16% of sales). Germany sales rose 5.2% YoY to INR3b (9% of sales).
- Gross margin contracted 75bp at 75.8% for 2QFY26.
- EBITDA margin expanded 30bps YoY to 32.8%, as the increase in RM costs (up 75bps YoY as a % of sales)/employee costs (up 20bps YoY as a % of sales) was offset by lower other expenses (down 125bps YoY as a % of sales).
- Accordingly, EBITDA grew 15.3% YoY to INR10.8b (vs our Est: INR10.7b).
- Adj. PAT grew 32.6% YoY to INR6b. Exceptional item pertains to regulatory/statutory fees.
- For 1HFY26, Revenue/EBITDA/PAT grew 13%/14%/17% YoY

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)
Research Analyst – Eshita Jain (Eshita.Jain@MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilaloswal.com)

Highlights from the management commentary

- TRP delivered volume/new launches/price YoY growth of 3.7%/3%/5.5% in the DF segment for the quarter.
- The company delivered 13% YoY growth in the chronic segment vs industry YoY growth of 11%. The outperformance was driven by a superior show in therapies like cardiac and gastro.
- TRP's DF segment faced minimal impact from the GST transition during the quarter.
- TRP delivered 13% YoY CC growth in the Brazilian market vs the industry YoY growth of 7% in 2QFY26.
- The company has filed for Semaglutide in the Brazilian market. Given the product's relevance for the patient population, the Brazilian regulatory agency may prioritize Semaglutide submissions across companies.

Quarterly performance (Consolidated) **(INRm)**

Y/E March	FY25				FY26E				FY25	FY26	FY26E	Var.
INR m	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	vs Est
Net Revenues	**28,590**	**28,890**	**28,090**	**29,590**	**31,780**	**33,020**	**32,498**	**33,030**	**115,160**	**130,328**	**32,165**	**2.7**
YoY Change (%)	10.3	8.6	2.8	7.8	11.2	14.3	15.7	11.6	7.3	13.2	11.3	
EBITDA	**9,240**	**9,390**	**9,140**	**9,810**	**10,470**	**10,830**	**10,497**	**10,768**	**37,580**	**42,565**	**10,679**	**1.4**
YoY Change (%)	16.8	13.8	5.2	11.1	13.3	15.3	14.8	9.8	11.6	13.3	13.7	
Margins (%)	32.3	32.5	32.5	33.2	32.9	32.8	32.3	32.6	32.6	32.7	33.2	
Depreciation	1,970	1,980	1,990	2,010	2,010	2,040	2,107	2,142	7,950	8,299	2,210	
EBIT	**7,270**	**7,410**	**7,150**	**7,800**	**8,460**	**8,790**	**8,389**	**8,626**	**29,630**	**34,265**	**8,469**	**3.8**
YoY Change (%)	21.2	18.8	9.0	14.7	16.4	18.6	17.3	10.6	15.7	15.6	14.3	
Margins (%)	25.4	25.6	25.5	26.4	26.6	26.6	25.8	26.1	25.7	26.3	26.3	
Interest	750	640	570	560	560	480	520	510	2,520	2,070	540	
Other Income	240	-160	330	-180	-370	-270	182	171	230	-287	175	
PBT before EO Expense	**6,760**	**6,610**	**6,910**	**7,060**	**7,530**	**8,040**	**8,051**	**8,287**	**27,340**	**31,908**	**8,104**	**-0.8**
One-off expenses	200	0	0	410	150	130	0	0	610	280	0	
PBT after EO Expense	**6,560**	**6,610**	**6,910**	**6,650**	**7,380**	**7,910**	**8,051**	**8,287**	**26,730**	**31,628**	**8,104**	
Tax	1,990	2,080	1,880	1,670	1,900	2,000	2,069	2,163	7,620	8,132	2,123	
Rate (%)	29.4	31.5	27.2	23.7	25.2	24.9	25.7	26.1	27.9	25.5	26.2	
Reported PAT	**4,570**	**4,530**	**5,030**	**4,980**	**5,480**	**5,910**	**5,982**	**6,124**	**19,110**	**23,496**	**5,980**	**-1.2**
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	
Adj PAT	**4,709**	**4,530**	**5,030**	**5,287**	**5,591**	**6,007**	**5,982**	**6,124**	**19,556**	**23,705**	**5,980**	**0.4**
YoY Change (%)	24.6	17.4	31.9	17.8	18.7	32.6	18.9	15.8	22.7	21.2	32.0	
Margins (%)	16.5	15.7	17.9	17.9	17.6	18.2	18.4	18.5	17.0	18.2	18.6	

Key performance Indicators (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var.
INRm	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE			2QE	vs Est
India formulations	16,350	16,320	15,810	15,450	18,110	18,200	17,944	17,690	63,930	71,945	18,132	-0.38
YoY Change (%)	14.7	13.0	11.7	12.0	10.8	11.5	13.5	14.5	12.8	12.5	11.1	
US generics	2,590	2,680	2,710	3,020	3,080	3,370	3,320	3,569	11,000	13,339	3,071	-8.87
YoY Change (%)	-11.6	8.1	-1.1	15.3	18.9	25.7	22.5	18.2	2.0	21.3	14.6	
Latin America	1,960	2,630	2,910	3,510	2,180	3,180	3,434	3,686	11,000	12,479	3,090	-2.82
YoY Change (%)	3.2	4.4	-6.7	-5.6	11.2	20.9	18.0	5.0	-2.3	13.4	17.5	
Europe	2,840	2,880	2,820	2,860	3,080	3,030	2,961	3,003	11,390	12,074	2,966	-2.10
YoY Change (%)	10.1	8.3	4.4	2.1	8.5	5.2	5.0	5.0	6.1	6.0	3.0	
Others (ROW+CDMO)	4,850	4,380	3,840	4,750	5,330	5,240	4,838	5,083	17840	20491	4,905.6	-6.38
YoY Change (%)	14.4	-2.7	-16.7	5.3	9.9	19.6	26.0	7.0	0.0	14.9	12.0	
Cost Break-up												
RM Cost (% of Sales)	24.3	23.5	24.0	24.1	24.4	24.2	24.2	23.9	24.4	24.2	24.1	
Staff Cost (% of Sales)	19.2	18.8	19.5	19.0	19.0	19.0	19.3	19.0	19.5	19.1	18.2	
Other Cost (% of Sales)	24.2	25.2	24.0	23.8	23.7	24.0	24.2	24.5	24.7	24.1	24.5	
Gross Margins(%)	75.7	76.5	76.0	75.9	75.6	75.8	75.8	76.1	75.6	75.8	75.9	
EBITDA Margins(%)	32.3	32.5	32.5	33.2	32.9	32.8	32.3	32.6	32.6	32.7	33.2	
EBIT Margins(%)	25.4	25.6	25.5	26.4	26.6	26.6	25.8	26.1	25.7	26.3	26.3	

Torrent Pharma

Secondary sales grew 6.6% YoY in Sep'25 vs. 7.1% in Aug'25. Robust growth in Nikoran/Nexpro and Nexpro - Rd was partially offset by a decline in Shelcal Xt /Unienzyme/ Losar and muted performance in Shelcal and Nebicard in Sep'25.

Exhibit 1: Top 10 drugs

Drug	Therapy	MAT Sep'25 Value (INR m)	MAT Sep'25 Growth (%)	MAT Sep'25 Market share (%)	Growth (%) Last 3M	Growth (%) Sep'25
Total		**83,109**	**7.9**	**100.0**	**6.7**	**6.6**
Shelcal	Vitamins/Minerals/Nutrients	3,366	-4.4	33.6	2.2	3.9
Chymoral	Pain / Analgesics	3,257	1.3	88.6	1.7	7.6
Nexpro-Rd	Gastro Intestinal	2,593	15.5	25.3	11.0	11.2
Nikoran	Cardiac	2,358	14.3	52.9	20.1	20.6
Shelcal Xt	Vitamins/Minerals/Nutrients	2,332	1.6	20.1	-5.1	-5.1
Unienzyme	Gastro Intestinal	1,645	-2.5	41.0	-3.2	-2.8
Nebicard	Cardiac	1,456	3.8	53.1	4.6	4.6
Nexpro	Gastro Intestinal	1,392	21.5	29.8	18.4	18.9
Losar	Cardiac	1,389	2.6	61.8	-1.4	-2.7
Veloz-D	Gastro Intestinal	1,304	5.4	10.3	5.1	5.9

* Three-months: Jul–Sep'25 Source: IQVIA, MOFSL

Strong growth in Neuro and Cardiac was partially offset by moderate performance in VMN/Pain and Anti-Diabetic in Sep'25.

Growth was driven by price hikes on a MAT Sep'25 basis.

Exhibit 2: Therapy mix (%)

	Share	MAT growth (%)	3M*	Sep'25
Total	**100.0**	**7.9**	**6.7**	**6.6**
Cardiac	27.6	11.0	9.2	8.3
Gastro Intestinal	17.9	9.2	6.5	7.0
Neuro / Cns	14.9	10.6	9.3	10.0
Vitamins/Minerals/Nutrients	9.5	1.6	3.7	4.9
Anti Diabetic	9.3	13.4	6.0	5.0
Pain / Analgesics	7.9	2.6	3.9	6.8

Source: IQVIA, MOFSL

Exhibit 3: Acute vs. Chronic (MAT growth)



Source: IQVIA, MOFSL

Exhibit 4: Growth distribution (%) (MAT Sep'25)



Source: IQVIA, MOFSL

Key takeaways from the management interaction

- TRP has a target to file 4-5 ANDAs in FY26 and 10 in FY27.
- Germany continues to face supply disruptions from its third-party supplier, with normalization expected by 4QFY26.
- CCI approval is in place for the JB Pharma acquisition. Overall transaction is expected to be completed by Jan'26.
- Capex for 1HFY26 was ~INR2b and INR3b for FY26.
- TRP is on track to expand field force to 7k by FY26.
- TRP plans to enter a new therapeutic area by 4QFY26 in the DF segment.

Key exhibits

Exhibit 5: US sales rose 21.9% YoY in 2QFY26 (CC terms)



Source: MOFSL, Company

Exhibit 6: India sales grew ~11.5% YoY in 2QFY26



Source: MOFSL, Company

Exhibit 7: Germany sales grew 5.2% YoY in 2QFY26



Source: Company, MOFSL

Exhibit 8: Brazil's revenue grew 20.9% YoY in 2QFY26



Source: Company, MOFSL

Exhibit 9: EBITDA margin expanded marginally 30bp YoY in 2QFY26



Source: MOFSL, Company

Exhibit 10: Adjusted PAT rose ~32.6% YoY in 2QFY26



Source: MOFSL, Company

Brazil on a strong growth trajectory/US showing signs of revival

DF – Chronic focus execution to drive sustainable growth

- In 1HFY26, TRP's India business grew 11% YoY to INR36.3b, maintaining the same growth trajectory as FY25.
- The TRP chronic portfolio grew 13% YoY, outperforming the industry's 11% YoY growth, driven by a strong performance in cardiac and gastro therapies.
- TRP experienced minimal impact from the GST transition on DF sales this quarter.
- TRP plans to expand MR strength to ~7,000 by end FY26, with maximum additions to support chronic/sub-chronic divisional expansion. TRP is exploring newer therapies and will be making inroads targeted by end-4QFY26/early-FY27.
- As per IQVIA, cardiac/CNS segments grew 9.2%/9.3% YoY in 2QFY26 for TRP.
- The OTC business grew 27% YoY in 1HFY26 vs 29% YoY in 2QFY26, driven by increased ad spends/wider field force coverage in underpenetrated regions.
- TRP expects India business to continue outperforming industry growth on the back of new product launches/improving field force productivity/market share gains in chronic therapies such as cardiac/diabetes/CNS.
- Accordingly, we expect a 14.7% sales CAGR in DF to INR96.4b over FY25-28.

Brazil – New launches including Semaglutide - a potential growth opportunity

- In 1HFY26, the Brazilian business grew 17% YoY to INR5.3b. The performance was aided by the performance of top brands and new launches.
- TRP's Brazil business maintained strong growth momentum, with revenue rising 14% YoY in CC to BRL340m in 1HFY26 vs 9% CC growth recorded in FY25.
- TRP currently has 65 products under *ANVISA* review.
- Semaglutide has been filed with *ANVISA* in Brazil. The potential launch represents a major growth opportunity with TRP, aiming for a 10-15% market share in ~USD1b market. However, timelines remain dependent on regulatory approval.
- Accordingly, we expect a 14.2% sales CAGR over FY25-28, reaching INR16.4b.

US – Growth momentum regaining traction

- After two consecutive years of subdued performance in US generics, 1HFY26 has shown clear signs of recovery.

- Compared to just 2% YoY growth in FY25, TRP exhibited 22% YoY growth in US generics sales to INR6.4b in 1HFY26. In cc terms, it exhibited 19% YoY growth.
- Growth is being driven by new product launches, where target market shares have been achieved along with higher purchase volumes under existing supply contracts.
- On the back of new launches/R&D efforts to enhance the ANDA pipeline, we expect an 18% sales CAGR over FY25-28, reaching INR18.1b.

Reiterate Neutral

- We largely maintain our estimates for FY26/FY27/FY28. We value TRP at 40x 12M forward earnings to arrive at a TP of INR3,770. TRP remains well-positioned to deliver industry-leading growth in DF/LATAM.
- While current product launches have driven US growth, the pace of filings is expected to pick up from FY27 onwards. The temporary disruption will continue to impact the EU business in the near term. Considering all these factors, we expect a 13%/16%/23% revenue/EBITDA/PAT CAGR over FY25-28. Integration and synergy benefits from the JB acquisition are expected to materialize post completion of the acquisition process. Considering the limited upside from current levels, we reiterate **Neutral** on the stock.

Exhibit 11: P/E chart



Source: MOFSL, Company, Bloomberg

Exhibit 12: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg

Story in charts

Exhibit 13: Expect total sales CAGR of 13% over FY25-28



Source: Company, MOFSL

Exhibit 14: EBITDA margin to expand 225bp over FY25-28



Source: Company, MOFSL

Exhibit 15: Expect 14.7% DF sales CAGR over FY25-28



Source: Company, MOFSL

Exhibit 16: Expect 19% US sales (USDm) CAGR over FY25-28



Source: Company, MOFSL

Exhibit 17: Expect ~14.2% sales CAGR in Brazil over FY25-28



Source: Company, MOFSL

Exhibit 18: Expect 13.6% sales CAGR in Germany over FY25-28



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26E**	**FY27E**	**FY28E**
Net Sales	**85,080**	**95,820**	**107,280**	**115,160**	**130,328**	**143,351**	**166,393**
Change (%)	6.3	12.6	12.0	7.3	13.2	10.0	16.1
EBITDA	**24,310**	**28,288**	**33,680**	**37,580**	**42,565**	**49,169**	**58,071**
Margin (%)	28.6	29.5	31.4	32.6	32.7	34.3	34.9
Depreciation	6,620	7,070	8,080	7,950	8,299	8,995	9,288
EBIT	**17,690**	**21,218**	**25,600**	**29,630**	**34,265**	**40,174**	**48,783**
Int. and Finance Charges	2,550	3,330	3,540	2,520	2,070	1,729	1,176
Other Income - Rec.	1,970	850	580	230	-287	1,050	1,150
PBT before EO Expense	**17,110**	**18,738**	**22,640**	**27,340**	**31,908**	**39,495**	**48,757**
EO Expense/(Income)	4,850	267	-880	610	280	0	0
PBT after EO Expense	**12,260**	**18,471**	**23,520**	**26,730**	**31,628**	**39,495**	**48,757**
Current Tax	4,490	6,110	6,959	7,618	8,130	10,859	13,504
Deferred Tax	0	0	1	2	2	2	2
Tax	4,490	6,110	6,960	7,620	8,132	10,861	13,506
Tax Rate (%)	26.2	32.6	30.7	27.9	25.5	27.5	27.7
Reported PAT	**7,770**	**12,361**	**16,560**	**19,110**	**23,496**	**28,634**	**35,252**
Adj PAT	**11,617**	**12,581**	**15,942**	**19,556**	**23,705**	**28,634**	**35,252**

Balance Sheet							(INR m)
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26E**	**FY27E**	**FY28E**
Equity Share Capital	850	1,692	1,692	1,692	1,692	1,692	1,692
Total Reserves	58,680	60,288	66,868	74,218	89,360	107,652	130,172
Net Worth	**59,530**	**61,980**	**68,560**	**75,910**	**91,052**	**109,344**	**131,864**
Deferred liabilities	-4940	-5440	-5548	2340	2340	2340	2340
Total Loans	40,180	52,970	39,380	30,260	25,380	18,380	11,380
Capital Employed	**94,770**	**109,510**	**102,392**	**108,510**	**118,772**	**130,064**	**145,584**
Gross Block	104,548	127,128	138,405	143,978	147,478	150,481	153,981
Less: Accum. Deprn.	37,298	44,368	52,448	60,398	69,294	78,289	87,577
Net Fixed Assets	**67,250**	**82,760**	**85,957**	**83,580**	**78,184**	**72,191**	**66,403**
Capital WIP	6,720	8,330	2,810	3,670	3,670	3,670	3,670
Investments	440	450	350	470	470	470	470
Curr. Assets	**51,650**	**53,140**	**56,110**	**56,230**	**75,886**	**98,095**	**126,776**
Inventory	24,620	22,300	22,790	25,410	28,569	31,465	36,220
Account Receivables	16,330	19,440	18,440	18,670	22,156	25,803	29,951
Cash and Bank Balance	4,030	5,710	8,390	5,790	18,127	33,048	52,001
Loans & Advances	6,670	5,690	6,490	6,360	7,034	7,779	8,604
Curr. Liability & Prov.	**31,290**	**35,170**	**42,837**	**35,440**	**39,436**	**44,362**	**51,735**
Account Payables	23,490	27,300	34,387	26,350	30,064	32,937	37,656
Provisions	7,800	7,870	8,450	9,090	9,373	11,425	14,079
Net Current Assets	**20,360**	**17,970**	**13,273**	**20,790**	**36,450**	**53,733**	**75,041**
Appl. of Funds	**94,770**	**109,510**	**102,390**	**108,510**	**118,773**	**130,064**	**145,584**

E: MOFSL Estimates

Financials and valuations

Ratios							
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26E**	**FY27E**	**FY28E**
EPS	**34.3**	**37.2**	**47.1**	**57.8**	**70.0**	**84.6**	**104.2**
Cash EPS	42.5	57.4	72.8	159.9	187.9	222.4	263.2
BV/Share	175.9	183.1	202.6	448.6	538.1	646.2	779.2
DPS	10.3	11.2	14.1	17.3	21.0	25.4	31.2
Payout (%)	54.0	36.8	34.8	37.0	36.4	36.1	36.1
Valuation (x)							
P/E	104.3	96.3	76.0	62.0	51.1	42.3	34.4
Cash P/E	84.2	62.4	49.2	22.4	19.1	16.1	13.6
P/BV	20.4	19.5	17.7	8.0	6.7	5.5	4.6
EV/Sales	14.7	13.1	11.6	10.7	9.4	8.3	7.0
EV/EBITDA	51.3	44.5	36.9	32.9	28.6	24.3	20.2
Dividend Yield (%)	0.3	0.3	0.4	0.5	0.6	0.7	0.9
FCF per Share	94.5	57.7	87.7	58.9	83.6	99.5	116.8
Return Ratios (%)							
RoE	19.7	20.7	24.4	27.1	28.4	28.6	29.2
RoCE	14.9	13.9	16.3	20.1	22.7	24.5	26.6
RoIC	16.4	16.0	19.1	22.6	26.2	30.8	38.7
Working Capital Ratios							
Asset Turnover (x)	0.9	0.9	1.0	1.1	1.1	1.1	1.1
Fixed Asset Turnover (x)	1.2	1.3	1.3	1.4	1.6	1.9	2.4
Debtor (Days)	68	68	64	59	57	61	61
Inventory (Days)	106	85	78	81	80	80	79
Working Capital Turnover (Days)	70	47	17	48	51	53	51
Leverage Ratio (x)							
Interest Cover Ratio	6.9	6.4	7.2	11.8	16.6	23.2	41.5
Debt/Equity	0.7	0.9	0.6	0.4	0.3	0.2	0.1

Cash Flow Statement							(INR m)
Y/E March	**FY22**	**FY23**	**FY24**	**FY25**	**FY26E**	**FY27E**	**FY28E**
Oper. Profit/(Loss) before Tax	12,259	18,472	23,521	26,730	31,908	39,495	48,757
Depreciation/Amorisation	6,622	7,066	8,083	7,950	8,299	8,995	9,288
Interest/Dividends Recd.	2,479	3,187	3,421	2,320	2,357	679	26
Direct Taxes Paid	-4,210	-3,981	-4,981	-6,030	-8,130	-10,859	-13,504
(Inc)/Dec in WC	-3,519	-182	4,181	-2,710	-2,931	-3,670	-4,184
CF from Operations	**13,631**	**24,561**	**34,224**	**28,260**	**31,503**	**34,640**	**40,383**
Others Items	4,399	-880	-1,564	-2,410	283	2,053	2,654
CF from Operating incl EO Expense	**18,030**	**23,681**	**32,661**	**25,850**	**31,786**	**36,693**	**43,037**
(inc)/dec in FA	-1,958	-4,152	-2,991	-5,930	-3,500	-3,003	-3,500
Free Cash Flow	**16,072**	**19,529**	**29,670**	**19,920**	**28,286**	**33,690**	**39,537**
(Pur)/Sale of Investments	-348	474	331	350	0	0	0
Others Items	345	-19,675	1,062	180	-674	-745	-825
CF from Investments	**-1,961**	**-23,354**	**-1,598**	**-5,400**	**-4,174**	**-3,748**	**-4,325**
Issue of shares	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-8,464	12,434	-13,933	-9,530	-4,880	-7,000	-7,000
Interest Paid	-2,577	-3,030	-3,710	-2,620	-2,357	-679	-26
Dividend Paid	-6,769	-8,630	-10,153	-10,830	-8,559	-10,339	-12,729
Others Items	0	0	0	0	521	-6	-5
CF from Fin. Activity	**-17,811**	**774**	**-27,796**	**-22,980**	**-15,275**	**-18,024**	**-19,759**
Inc/Dec of Cash	**-1,742**	**1,101**	**3,266**	**-2,530**	**12,337**	**14,921**	**18,953**
Opening Balance	5,726	3,984	5,085	8,351	5,730	18,067	32,988
Add/(less) Forex in Cash/Cash eq				-91	0	0	0
Closing Cash and Cash Eq.	**3,984**	**5,085**	**8,351**	**5,730**	**18,067**	**32,988**	**51,941**
Bank balances*	50	630	40	60	60	60	60
Total Cash and Cash Eq.	**4,034**	**5,715**	**8,391**	**5,790**	**18,127**	**33,048**	**52,001**

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:
The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:
a) received any compensation/other benefits from the subject company of this report
b) managed or co-managed public offering of securities from subject company of this research report,
c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:
a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.
To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:
This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	**Torrent Pharma**
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:
This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.
MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and

interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL .

Disclaimer:
The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.